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Abstract
Background: Experimental evidence suggests that matrix metalloproteinase-13 (MMP-13) protein may promote breast
tumor progression. However, its relevance to the progression of human breast cancer is yet to be established.
Furthermore, it is not clear whether MMP-13 can be used as an independent breast cancer biomarker. This study was
conducted to assess the expression profile of MMP-13 protein in invasive breast carcinomas to determine its diagnostic
and prognostic significance, as well as its correlation with other biomarkers including estrogen receptor (ER),
progesterone receptor (PR), Her-2/neu, MMP-2, MMP-9, tissue inhibitor of MMP-1 and -2 (TIMP-1 and TIMP-2).
Methods: Immunohistochemistry (IHC) was performed on paraffin-embedded tissue microarray containing specimens
from 263 breast carcinomas. The intensity and the extent of IHC were scored by pathologists in blind fashion. The
correlation of the gene expression profiles with patients' clinicopathological features and clinical outcomes were analyzed
for statistical significance.
Results: MMP-13 protein was detected in the cytoplasm of the malignant cells and the peritumoral stromal cells. MMP-
13 expression by tumor cells (p < 0.001) and stromal fibroblasts (p <0.001) both correlated with carcinoma infiltration
of lymph nodes. MMP-13 also correlated with the expression of Her-2/neu (p = 0.015) and TIMP-1 (p < 0.010),
respectively in tumor cells. Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor
phenotypes. Moreover, high levels of MMP-13 expression were associated with decreased overall survival. In parallel, the
prognostic value of MMP-13 expressed by peritumoral fibroblasts seems less significant. Our data suggest that lymph
node status, tumor size, Her-2/neu expression, TIMP-1 and MMP-13 expression in cancer cells are independent
prognostic factors.
Conclusion: Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor phenotypes,
and inversely correlated with the overall survival of breast cancer patients. MMP-13 may serve as an independent
prognostic factor for invasive breast cancer patients. MMP-13 may be particularly useful as a prognostic marker when
evaluated along with Her-2/neu and lymph node status.
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Background
Breast cancer is one of the leading causes of cancer death
among women worldwide. Of particular significance, the
incidence and mortality rate of breast cancer increased
sharply in China over the last couple of decades [1]. Clin-
ical parameters, such as the size of the primary tumor, the
histological grade, and regional lymph node involvement,
are generally useful for predicting the prognosis. How-
ever, the profile of molecular markers may provide valua-
ble insights into the underlying mechanisms of disease
progression, thus aiding the intervention strategies. In
light of the racial disparities of breast cancer incidences
and prognoses documented in the literature, it is impor-
tant to identify and validate specific biomarkers for Chi-
nese breast cancer patients. To this end, estrogen receptor
(ER)/progesterone receptor (PR), and oncogene Her-2/
neu have been shown to be useful markers of breast can-
cer [2,3].
Breast cancer mortality derives overwhelmingly from
invasion and metastasis, a process that requires continu-
ous and extensive remodeling of tumor stroma. Epithelial
basement membrane and extracellular matrix (ECM) are
composed of tough network of fibrillar ECM proteins that
can be directly degraded only by divalent cation-depend-
ent matrix metalloproteinses (MMPs). Not surprisingly,
experimental evidence supports a critical role of MMPs,
such as MMP-2 and MMP-9, in the invasion and metasta-
sis of breast cancer [4]. MMP-13, also named collagenase-
3, is another MMP that is implicated in the degradation of
ECM [5,6]. Recent studies further suggests that MMP-13
may play a central role in the extracellular MMP activation
cascade [7,8]. It has been reported that overexpression of
MMP-13 in several types of malignancy [9-17] is associ-
ated with shorter overall survival of the patients
[16,18,19]. Consistently, functional evidence demon-
strates that MMP-13 increases the invasive capacities of
the malignant cells [20-24]. Interestingly, the clinical util-
ity of MMP-13 as a breast cancer marker remains contro-
versy. While several studies conclude that MMP-13 is
produced by tumor stromal fibroblast-like cells [5], others
claim that MMP-13 is synthesized predominantly by
tumor cells [25]. For example, Balduyck, et al, demon-
strated that MMP-13 was expressed in more invasive
breast carcinoma cells [21]. Nielsen and colleagues
showed that MMP-13 was expressed in myofibroblasts
[25,26].
The goal of current study was to evaluate the prognostic
values of MMP-13 expression level and its tissue distribu-
tion pattern in a large cohort of human breast cancer
patients. Our evidence demonstrates that increased
tumor-derived MMP-13 expression independently pre-
dicts poor prognoses. Furthermore, the combination of
MMP-3 with other clinicopathological parameters and/or
other breast cancer biomarkers may be particularly useful.
Methods
Human sbjects and tssue secimens
The cohort includes a total of 263 cases of invasive breast
cancer, diagnosed and surgically treated between January
and December 1993 at the Department of Breast Cancer,
Tianjin Medical University Cancer Institute and Hospital
[27]. Patients had not received prior radiotherapy or neo-
adjuvant therapies. All patients received conventional
postoperative treatments, depending on the extents of the
disease. Patients without axillary lymph node involve-
ment were treated with operation alone, while patients
with axillary lymph node involvement received six
courses of adjuvant chemotherapy with cyclophospha-
mide/methotrexate/fluorouracil regiment. Patients with
positive nodes or tumor size ≥ 5 cm received postopera-
tive radiation. The patients with ER+/PR+  tumor were
treated for 2–5 years with tamoxifen.
The patient characteristics including age (median: 50.3
years), menopausal status, clinical stage (TNM classifica-
tion defined by the International Union against Cancer,
UICC, 2003) were assessed by the surgical pathologists.
These data as well as the postoperative follow-up informa-
tion including local (regional) recurrence and overall sur-
vival have been previously described [27]. Briefly, among
the 263 cases, 132 women were premenopausal, while
131 were postmenopausal. At the time of operation, 68
cases (25.9%) were Grade I tumors, 119 (45.25%) cases
were grade II tumors, and 76 cases (28.90%) were grade
III tumors. We used the commonly used grading standard
to assign the scores of histological grades of breast cancer.
Briefly, the tumor grading combines nuclear grade, tubule
formation and mitotic rate. Grade I is assigned to well-dif-
ferentiated tumors. Grade II is assigned to moderately dif-
ferentiated tumors. Grade III is assigned to poorly
differentiated tumors. Among the 263 cases, 45 cases
(17.1%) were classified of T1, 154 cases (58.6%) were T2,
59 cases (22.4%) were T3 and 5 (1.9%) cases were T4. A
total of 128 cases (48.%) were lymph node negative, 57
cases (21.7%) were N1, 26 cases (9.9%) were N2, and 52
case (19.8%) were N3. Local recurrence happened in 8
cases (3%). Metastases were identified in 54 cases
(20.5%), including 13 cases to the liver, 12 cases to the
bone, 11 cases to the lung, 7 cases to ipsilateral or the con-
tralateral suprascapular lymph nodes, 5 cases to the con-
tralateral breast, 2 cases to the brain, 2 cases to the ovary,
1 case to the pericardium, and 1 case to the pleura. All
patients, unless deceased, were followed up for at least 36
months, up to 173 months. The cases lost (due to patients'
death or other reasons) for follow-up had been marked as
censored data. Patient outcome was defined by the
months of post surgery overall survival (OS). This studyBMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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was performed under a protocol approved by the Tianjin
Medical University Administrative Panel on Human Sub-
jects in Medical Research and the Institutional Review
Boards of Tianjin Cancer Research institution.
Tissue mcroarrays (TMA) and imunohistochemistry (IHC)
TMA were constructed with a Beecher Instru-ments Tissue
Array (Beecher Instruments, Silver Spring, MD) as previ-
ously described [27]. Briefly, archival paraffin blocks of
invasive breast cancer cases. The recipient blocks were cut
into tissue cores of 0.6 mm in diameter. Two cores of each
specimen, representing the tumor areas, are transferred to
the donor blocks.
Consecutive 4 µm-thick sections were cut from the recipi-
ent blocks to a poly-L-lysine-coated slide for IHC analysis.
IHC was performed using a method as described previ-
ously [27]. A modification of antigen retrieval (5 min
high-power microwave followed by 10 min low-power
microwave in phosphate-buffered saline (PBS, PH 7.0)
was made for detecting MMP-2, MMP-9, MMP-13, TIMP-
1 and TIMP-2. The antibodies and the dilution factors
were as follows: MMP-13 (1: 150 diluted Clone VIIIA2
from Lab Vision Corp.), ER (1:450 diluted clone ID5 from
DAKO), PR (1:200 diluted clone IA6 from DAKO); Her2/
neu (1:1000 diluted polyconal from DAKO), MMP-2
(1:150 diluted polyclonal from Lab Vision Corp), MMP-9
(1:150 diluted polyclonal from Lab Vision Corp), TIMP-1
(1:150 diluted polyclonal from Lab Vision Corp), and
TIMP-2 (1:150 diluted polyclonal from Lab Vision Corp).
Human placenta tissue known to express high levels of
MMP-2, MMP-9 TIMP-1 and TIMP-2 [28,29] were used as
positive controls for these proteins, respectively. Breast
cancer cell lines MCF-7 and T47D were used as positive
control for ER and PR, respectively. Ovarian cancer cell
line SK-OV-3 was used as a positive control for Her-2/neu
staining [30]. PBS was used in the place of the primary
antibodies in all negative controls of IHC.
Semi-quantitative masurement of imunostaining
IHC was scored independently using a semi-quantitative
scoring system as described below by two pathologists
(WC and YL), who were both blinded to patients' clinico-
pathologic parameters and outcomes. Discordant scores
were re-evaluated by the investigators and the consensus
scores were used for further analyses. Both the intensity
and extent of IHC were assessed [27]. The intensity of the
immunostaining was defined by the negative and positive
controls as four categories. No brown particle staining: 0;
light brown particle in cytoplasm: 1; moderate brown par-
ticle: 2; and 3: dark brown particle. The percentage of pos-
itive cells, as the extent of immunostaining, was
quantified under microscope and classified into four
groups. 1: <25% positive cells; 2: 25% to 50% positive
cells; 3, 51% to 75% positive cells and 4, >75% positive
cells. The staining index (SI), the product of the intensity
and the percentage of positive staining, was used to define
high (SI ≥ 6) or low (SI < 6) expression of MMP-13, MMP-
2, MMP-9, TIMP-1 and TIMP-2.
The criterion of Herceptest/Pathway system was followed
to score Her-2/neu Briefly, cases with strong complete
membranous staining in more than 10% of the tumor
cells were considered strongly positive (+3). Cases with
weak to moderate complete membranous staining in
more than 10% of the tumor cells were considered mod-
erately positive (+2) and were subsequently confirmed by
fluorescence in situ hybridization. Cases with little or no
membranous staining were considered negative (0 or +1)
[31]. The criteria for scoring of ER and PR are similar.
Cases with strong/moderate complete nuclear staining in
more than 15% of the tumor cells were considered posi-
tive, whereas cases with little or no nuclear staining were
considered negative [27,31].
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware package 11.0 (SPSS, Inc. Chicago, IL, USA). The cor-
relations between MMP-13 expression and
clinicopathologic variables were analyzed using Pearson
Chi-square analysis. The same method was used to test the
associations of MMP-13 with ER, PR, and Her-2/neu,
respectively. Kaplan-Meier curves were constructed for
univariate and multivariate analyses using a Cox propor-
tional hazards model to examine the potential prognostic
variables on OS. No corrections for multiple comparisons
were made. All of the statistical tests were two-sided. p val-
ues of less than 0.05 were considered statistically signifi-
cant.
Results
Breast cancer cells and peritumoral fibroblasts both 
express MMP-13
Distinct IHC staining of MMP-13 was obtained from all
263 cases. The tumor or fibroblast-specific staining was
semi-quantitatively scored by the SI scales and assigned
into high and low categories. As shown in Figure 1, MMP-
13 protein expression was detected mainly in cytoplasm
of in malignant cells and the peritumoral fibroblasts in
127 (48.29%) and 144 (54.75%) cases, respectively. One
hundred and eleven out of 127 specimens with high levels
of tumor expression of MMP-13 (87.40%) featured high
levels of MMP-13 in peritumoral fibroblasts. Consistently,
106 out of 144 specimens with low levels of tumor expres-
sion of MMP-13 were accompanied by peritumoral
fibroblasts that expressed MMP-13 at low levels (Table 1).
Overall, the detection of cytoplasmic MMP-13 in tumor
cells, correlated significantly with the cytoplasmic MMP-3
in the peritumoral fibroblasts (p < 0.0001).BMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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MMP-13 correlates with lymph node infiltration and Her-
2/neu expression
To test the potential value of MMP-13 as a breast cancer
biomarker, we performed Pearson Chi-square analysis to
evaluate the correlation of MMP-13 expression with clini-
cal and histopathological features (tumor size, tumor
grade, and lymph node status) that are further stratified as
shown in Table 2. p values of less than 0.05 was consid-
ered statistically significant. High levels of MMP-13
expression, both in cancer cells and in peritumoral fibrob-
lasts, correlated with lymph node metastases (p < 0.001),
but not with tumor size and histological grade. MMP-13
did not appear to be regulated by sexual steroid hor-
mones, since it was not correlated with the menopausal
statuses of the patients. Nor was it correlated with ER or
PR. Interestingly, a strong correlation between MMP-13,
both in cancer cells (p = 0.015) and peritumoral fibrob-
lasts (p < 0.001), was observed with Her-2/neu nuclear
staining.
MMP-13 correlated with TIMPs, but not with MMP-2 and 
MMP-9
Biochemically redundant members of the MMP family
may have intricate interplay in tumor progression. To
begin to understand the relative significance of MMP-13,
we examined its correlation with other MMPs (MMP-2
and MMP-9) and tissue inhibitors of MMP (TIMP-1 and
TIMP-2). Distinct IHC staining of each of these proteins
were detected in the cytoplasm of both the cancer cells
and adjacent fibroblasts (Figure 2). MMP-13 detected
either in cancer cells or in adjacent fibroblasts, was not
correlated with MMP-2 or MMP-9 (Table 2). Thus, the dif-
ferential expression of MMP-13 in breast tumor progres-
sion may be regulated by a mechanism different from
those for MMP-2 and MMP-9. High levels of MMP-13 in
both cancer cells (p < 0.010) and peritumoral fibroblasts
(p  = 0.002), significantly correlated with the levels of
TIMP-1 protein in the same specimens. In addition, MMP-
13 in peritumoral fibroblasts correlated to lesser extent,
albeit significant, with the levels of TIMP-2 protein (p =
0.029).
MMP-13 negatively correlates with breast cancer OS
The mean follow-up of the 263 patients in our cohort is
92.1 months. Kaplan-Meier analyses showed a clear strat-
ification of the OS between the patients with high levels
of MMP-13 expression and the patients with low levels of
MMP-13 expression (Table 3). High levels of MMP-13
Differential expression of MMP-13 in breast cancer and peritumoral fibroblast cells Figure 1
Differential expression of MMP-13 in breast cancer and peritumoral fibroblast cells. Invasive ductal carcinoma fea-
tured MMP-13 protein in the cytoplasm of both the cancer cells and peritumoral fibroblast cells (A). High levels of MMP-13 
protein exclusively in the cytoplasm of the cancer cells (B). The brown color represents the IHC staining of MMP-13. The blue 
color represents the nuclear counterstain. × 400. Insets of A and B show a section of the each field with higher magnification. 
× 1000.
Table 1: Correlation of tumor-derived MMP-13 with stromal 
fibroblast-derived MMP-13
Stromal Fibroblast-derived MMP-13
Low High pR
n%n%
Tumor-derived Low 103 75.7 33 24.3 < 0.001 0.634
MMP-13 High 16 12.6 111 87.4
Low: immunostaining SI < 6; High immunostaining SI > 6; n: number of 
the casesBMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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expression both in the cancer cells (p = 0.0008) and the
neighboring fibroblasts (p = 0.0001) negatively correlated
with OS (Figure 3A and 3B). Tumor expression of MMP-
13 negatively correlated with patients' OS regardless of the
Her-2/neu status. It was noted that MMP-13 detected in
peritumoral fibroblasts correlated with the OS of the
lymph node positive subgroup (p = 0.047) and with the
Her-2/neu negative subgroups (p = 0.045) (Figure 3C–F).
When the patients' survival was stratified by lymph node
status, MMP-13 expression was negatively correlated with
the OS of the lymph node positive subgroups (p  =
0.0041), but not with the OS of the lymph node negative
subgroups (p = 0.344).
In the Cox regression model, univariate survival analyses
showed that tumor size, lymph node positivity (>N2), PR,
Her-2/neu, TIMP-1 and MMP-13 were each associated
with worse prognoses, while, multivariate survival analy-
ses showed that lymph node positivity (>N2), tumor size,
Her-2/neu, MMP-13 and TIMP-1 expression by cancer
cells were independent adverse prognostic factors for
overall survival (Table 4). Parallel analyses showed that
ER and Tumor Grades were not correlated with OS.
Discussion
Predicting patients' prognoses is clearly one the most chal-
lenging issues in breast cancer treatments. Racial, geo-
graphical and dietary factors have all been considered for
their impacts on breast cancer incidences and survival.
However, at the histopathological level, breast cancer is a
highly heterogeneous disease, hampering the prognosis
predictions. Histological grading, as shown by others and
Table 2: Correlation of high MMP-13 expression with clinicopathological parameters and other biomarkers
High MMP-13 expression
Cancer Cells Stromal Fibroblasts
Parameters/Markers Total n % pn % p
Menopausal
Pre-menopausal 132 64 48.5 0.949 70 53.0 0.573
Post-menopausal 131 63 48.1 71 56.5
Tumor Size
<2 cm 46 25 54.3 0.365 28 60.9 0.359
>2 cm 217 102 47.0 116 53.5
Lymph Node Status
N0 128 43 33.6 < 0.001 55 43 < 0.001
N1 57 25 43.9 31 54.4
N2 26 17 65.4 16 61.5
N3 52 42 80.8 42 80.8
Histological Grade
G1 68 22 32.35 0.001 27 39.7 0.071
G2 119 56 47.06 67 56.3
G3 76 49 64.47 51 54.8
ER Status
Negative 101 51 50.5 0.572 56 55.4 0.859
Positive 162 76 46.9 88 54.3
PR Status
Negative 101 85 52.5 0.086 95 58.6 0.109
Positive 162 42 41.6 49 485
HER2/neu Protein
Negative 211 94 44.5 0.0150 101 47.9 < 0.001
Positive 52 33 63.5 43 82.7
MMP-2 Protein
Negative 171 81 47.4 0.234 96 56.1 0.927
Positive 51 29 56.9 29 56.9
MMP-9 Protein
Negative 162 88 54.3 0.911 81 50.0 0.367
Positive 58 32 55.2 42 43.3
TIMP-1 expression
Negative 131 50 38.2 < 0.001 63 48.8 0.002
Positive 72 52 72.2 51 70.8
TIMP-2 Protein
Negative 41 15 36.6 0.080 52 35.6 0.029
Positive 142 74 52.1 34 51.5BMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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data in this paper, is not a reliable prognostic predictors.
To this end, hormone receptors (ER and PR) and Her-2/
neu have been used with certain degrees of success as the
biomarkers. In the current study, we examined a cohort of
263 Chinese breast cancer specimens and report the evi-
dence that MMP-13 correlated with more aggressive breast
cancer. Our data suggest that MMP13 may serve as a
marker for poor prognoses. To our knowledge, this is the
first IHC study to investigate the potential utility of MMP-
13 as a biomarker of breast cancer among Chinese
patients.
Our data support the earlier notion that MM-13 marked
the transition of ductal carcinoma in situ to invasive carci-
nomas [25] and increased the invasiveness of breast can-
cer cells in vitro [21]. The biological activity of MMP-13 in
tumor progression may not be limited to breast cancer.
For instance, Culhaci N et al, showed a significant correla-
tion of MMP-13 with the aggressiveness of head and neck
squamous carcinomas [20].
Although tumor cells are the ones that pass through mul-
tiple tissue barriers to metastasize, increasing evidence
demonstrates a critical role of stromal cells in tumor
microenvironments [32,33]. Vizoso FJ noted that MMP-
13 in fibroblastic cells and mononuclear immune cells
was associated with increased risks of metastases [34].
Interestingly, others have reported that MMP-13 protein
was restricted to small stromal foci within the tumor
masses and was specifically produced by invading tumor
cells [25]. In this study, we found MMP-13 protein in the
cytoplasm of both cancer cells and tumor-adjacent fibrob-
lasts. The expression of MMP-13 in cancer cells correlated
with the MMP-13 expression in the peritumoral fibrob-
Representative IHC of an infiltrating ductal carcinoma TMA Figure 2
Representative IHC of an infiltrating ductal carcinoma TMA. (A): MMP-2; (B): MMP-9; (C): TIMP-1; and (D): TIMP-
2. The brown staining represents the indicated antigen, while blue color is the counterstain of the nuclei. ×400.BMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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lasts. Furthermore, high levels of MMP-13 in cancer/peri-
tumoral fibroblast cells correlated with tumor infiltration
of lymph nodes. While this finding suggests that MMP-13
is likely to play a role in promoting tumor invasion and
metastasis, future studies are needed to clarify whether the
MMP-13 protein was expressed by both cancer cells and
fibroblasts or by tumor cells alone.
The two types of most widely accepted prognostic biomar-
kers for breast cancer are hormone receptor (ER and/or
PR) and oncoprotein Her-2/neu. ER is used to predict not
only the response to endocrine therapy but also better
overall survival. In contrast, Her-2/neu predicts more
aggressive tumor phenotype, poor disease-free survival
and poor OS [26,27]. High levels of MMP-13 in cancer
cells correlated with the expression of the Her-2/neu pro-
tein. Recently, similar results were reported by Ocharoen-
rat et al, with head and neck squamous cell carcinoma
specimens [35]. Currently, it is not known whether MMP-
13 is regulated by Her-2/neu. To this end, it is important
to note that MMP-13 seems to be of prognostic value even
for the Her-2/neu positive subset of cases, suggesting a
Her-2/neu-indepdent function of MMP-13 in promoting
breast cancer progression.
The correlation of MMP-13 with poor OS and tumor infil-
tration of lymph nodes suggests that it may promote
tumor invasion. Since MMP-13 is a metalloproteinase, it
may act in a similar manner as other MMPs, such as MMP-
2, MMP-9. In fact, both MMP-2 and MMP-9 have been
extensively studied as biomakers and as well as therapeu-
tic targets in breast cancer [36-39]. Interestingly, MMP-13
in both cancer cells and peritumoral fibroblast cells
showed no correlation with either MMP-2 or MMP-9.
Instead, we noted that MMP-13, both in cancer cells and
peritumoral fibroblast cells, correlated with TIMP-1 and
TIMP-2 (to a lesser extent). Thus, MMP-13 may be inde-
pendent of MMP-2 and MMP-9 as a marker as well as a
regulator of breast tumor progression. The intricate inter-
plays among MMPs and TIMPs could be more complex.
Indeed, in contrast to the initial simple biochemistry-
based hypothesis, TIMP-1 is viewed as a promising marker
to predict poor prognoses of human breast cancer [40-42].
The recent discovery of proteolysis-independent biologi-
cal functions of TIMPs, such as the growth-stimulating,
anti-apoptotic and pro-angiogenic properties, provided
new insights into this paradox [40-42]. Further studies are
needed to clarify whether MMP-13 and TIMPs act as cog-
nate partners or independent of each other.
Conclusion
This IHC study of TMA with 263 specimens of Chinese
breast cancer provided the first evidence that MMP-13 is
highly expressed by both the tumor cells and adjacent
fibroblast cells. High levels of MMP-13 in these two tissue
compartments were strongly correlated with each other,
and further correlated with Her-2/neu, TIMP-1, lymph
node metastasis and decreased overall survival. Our study
suggests a potential application of MMP-13 as an inde-
pendent biomarker for breast cancer prognosis.
Abbreviations
MMP: matrix metalloproteinase; TIMP: tissue inhibitor of
matrix metalloproteinase; ER: Estrogen Receptors; PR:
Progesterone Receptors; ECM: extracellular matrix; RFS:
relapse-free survival; OS: Overall survival; SI: staining
index
Table 3: Correlation of MMP-13 expression with OS of overall and stratified subpopulations.
MMP-13SI Tumor Stromal Fibroblast
n E OS (95% CI) p n E OS (95% CI) p
Overall
Low 133 20 153 (145~161) 0.0008 132 20 153(145~161) 0.0001
High 127 47 107 (98~116) 125 48 106 (97~115)
Node Status
Negative Low 82 8 135 (128~142) 0.3442 70 6 137 (131~143) 0.1231
High 43 7 122 (115~129) 55 10 128/(119~137)
Positive Low 50 12 142 (127~158) 0.0041  45 13 136 (118~153) 0.0494
High 82 40 93 (80~105) 87 39 97 (85~108)
HER2/neu
Negative Low 113 14 157 (149~165) 0.0092 106 15 155 (145~163) 0.0446
High 93 25 120 (111~129) 100 25 121 (113~130)
Positive Low 19 6 109 (85~133) 0.0154 9 4 96 (58~133) 0.5278
High 32 22 69 (50~88) 42 24 81 (64~98)
OS: Months of overall survival; n: Number of patients; E: Events of positive stains; CI: confidence interval.BMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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The prognostic significance of high MMP-13 protein expression in the entire patient population Figure 3
The prognostic significance of high MMP-13 protein expression in the entire patient population. The graphs show 
the effect of MMP-13 expression within cancer cells (A) and within peritumoral fibroblast cells (B) on patient overall survival 
(Log-rank test) and stratified analysis by lymph nodes status (C &D) and Her-2/neu status (E &F). Both high MMP-13 expres-
sion in cancer cells (A) and fibroblasts (B) associated with decreased overall survival (p = 0.0008 and 0.0001, respectively). 
When patients' OS were stratified by lymph node status and Her-2/neu status, MMP-13 expression in cancer cells was associ-
ated with reduced OS in the Her-2/neu positive and negative (E, p = 0.0092 and p = 0.0154, respectively) and lymph node pos-
itive subgroups (D, p = 0.0041). However, MMP-13 expressed within fibroblasts only weakly affected OS of lymph node 
positive (D) and Her-2/neu negative subgroups (F, p = 0.04694 and 0.04461, respectively)BMC Cancer 2008, 8:83 http://www.biomedcentral.com/1471-2407/8/83
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